- Celgene (NASDAQ:CELG) is up a fraction premarket on the heels of its announcement of positive results from a second Phase 3 clinical trial, RADIANCE, assessing ozanimod (formerly RPC1063) for the treatment of relapsing multiple sclerosis (RMS).
- The study met the primary endpoint of reducing annualized relapse rate compared to Biogen's (BIIB) Avonex (interferon beta-1a).
- The company reported successful results from its first Phase 3, SUNBEAM, in February.
- Detailed results will be submitted for presentation at an upcoming medical conference. Global regulatory filings will commence by year-end.
- Previously: Celgene's ozanimod successful in late-stage MS study; shares up a fraction premarket (Feb. 17)